Ocular Allergy

EyeGate Pharma announces first patient dosed in phase 2 ocular surface inflammation study

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Strategies to address challenging ocular infections

Delivering existing therapeutics through alternative routes may offer option.

Investigators zoom in on future of dry eye treatment

Autologous serum eye drops and blood products offer hope to patients.

Applying hydrogel technology to sustained-release ocular drugs

October 15, 2017

Hydrogel technology enables the use of drugs that are known to be efficacious for ocular diseases and conditions when formulated as daily drops or monthly injections, into one-time or several-month dosage forms.

New therapies needed for allergy symptoms, quality of life

October 08, 2017

Half of patients with ocular allergies report experiencing symptoms year-round. While nearly all of them take eye drops to treat their symptoms, the majority report limited or no effect from over-the-counter drops, according to a new survey. The results suggest that new treatment approaches would improve both symptoms and quality of life.

Topical cetirizine latest therapy to treat allergic conjunctivitis

August 04, 2017

Oral cetirizine is one of the most used oral medications for treatment of allergic rhinitis. In May 2017, the FDA approved the first ophthalmic formulation of the second-generation histamine-1 (H1) receptor antagonist for use in treating ocular itching associated with allergic conjunctivitis.